Clinical Trials Browser

Approved for marketing × Lymphoma, Large B-Cell, Diffuse × Clear all

NCT03153462 2023-11-08

ZUMA-9

Approved for marketing

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05733650 2023-05-25

Expanded Access Program for Epcoritamab

Approved for marketing

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04300803 2020-08-28

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Approved for marketing

Lymphoma, Large B-Cell, Diffuse